The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://fellowfavorite.com/story22012294/retatrutide-vs-tirzepatide-a-comparative-analysis